(MENAFN- PR Newswire) STOCKHOLM, March 4, 2024 /PRNewswire/ --
Medivir AB (NASDAQ STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Life Science Day in Gothenburg on March 6, 2024.
CEO Jens Lindberg will present Medivir with focus on data from the ongoing Phase 1b/2a clinical trial with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.
Medivir's presentation starts at 09.45 CET and can be viewed live on . The presentation will later be posted on this website and on YouTube.
The Life Science Day in Gothenburg is arranged for the eighth time. Those who want to participate physically in the event, which takes place at Wallenberg Conference Center, Sahlgrenska Academy, at Medicinareberget in Gothenburg, must register on no later than March 4.
After the meeting, the presentation will also be available on Medivir's website .
For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: [email protected]
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. .
The following files are available for download:
SOURCE Medivir
MENAFN04032024003732001241ID1107930120
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.